Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

26.64 +0.62 (+2.36%)
Streaming Delayed Price Updated: 12:50 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
From Novocure
Via Business Wire
Novocure to Report Third Quarter 2021 Financial Results
From Novocure
Via Business Wire
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
From Novocure
Via Business Wire
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
From Novocure
Via Business Wire
Novocure Appoints Bill Burke as Chief Human Resources Officer
From Novocure
Via Business Wire
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Novocure to Report Second Quarter 2021 Financial Results
From Novocure
Via Business Wire
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
From Novocure
Via Business Wire
Novocure Initiates Usability Study for Flexible Torso Array
From Novocure
Via Business Wire
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
From Novocure
Via Business Wire
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.